Delgado VT, Carnot UJ, de Castro AR, Muñío PJ, Hernández CC, Núñez QA, Pérez RG, Rodriguez FY

Idioma: Español
Referencias bibliográficas: 35
Paginas: 107-118
Archivo PDF: 160.89 Kb.

RESUMEN

Objetivo: analizar las causas de muerte en pacientes con diagnóstico de linfoma de Hodgkin.
Métodos: se realizó un estudio retrospectivo-descriptivo en el Servicio de Hematología del Hospital Clinicoquirúrgico "Hermanos Ameijeiras". La muestra quedó constituida por 443 pacientes, de los 619 diagnosticados desde enero de 1983 hasta diciembre del 2008, de ellos 287 (64,8 %) se encontraban vivos al final del estudio y 156 (35,2 %) habían fallecido.
Resultados: la recaída/progresión del linfoma de Hodgkin fue la causa más importante de muerte (125 pacientes, 80 %), independiente de la edad de presentación de la enfermedad, la modalidad de tratamiento empleada y el tiempo de evolución. El 20 % restante fue por segundas neoplasias en 10 pacientes (6,4 %), complicaciones del tratamiento en 8 (5,1 %), complicaciones infecciosas fatales en 2 (1,2 %) y enfermedad cardiovascular en 3 (1,9 %). En 8 pacientes (5,1 %) no se precisó la causa de muerte. Predominaron las segundas neoplasias en pacientes de 40-59 años, que recibieron la modalidad de tratamiento combinada y tenían menos de 10 años de evolución.
Conclusiones: la recaída/progresión del linfoma de Hodgkin permanece como causa más importante de muerte, independientemente de la edad de presentación, la modalidad de tratamiento empleada y el tiempo de evolución. Sería importante identificar precozmente los casos refractarios al tratamiento convencional para utilizar la modalidad terapéutica más apropiada para la curación.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Connors JM. Hodgkin’s Lymphoma. In: Goldman L, Schafer AI, editors. Goldman's Cecil Medicine. 24th ed. New York: Elsevier Saunder; 2012. p. 228-33.

2. Eichenauer DA, Engert A, Diehl V. Hodgkin lymphoma: clinical manifestations, staging, and therapy. In: Hoffman R, Benz EJ, Leslie E, Silberstein LE, editors. Hematology: Basic Principles and Practice. 6th ed. Philadelphia: Elsevier Saunder; 2013. p. 1138-56.

3. Provencio M, Millán I, España P. Analysis of competing risks of causes of death an their variation over different time periods in Hodgkin’s Disease. Clin Cancer Res. 2008;14:5300-05.

4. Goodman KA, Riedel E, Serrano V. Long-term effects of High dose chemotherapy and radiation for relapsed and refractary Hodgkin´s lymphoma. J Clin Oncol. 2008;26:5240-7.

5. Swerdlow A, Higgins C, Smith P. Myocardial infarction mortality risk after treatment for Hodgkin´s disease. J Nat Cancer Inst. 2007;99:206-14.

6. Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non Hodgkin lymphoma and myeloma in SEER Cancer Registries. Nat Cancer Inst. 2006;5:5302-8.

7. Hodgson D, Gilbert E, Dores G. Long-term solid cancer risk among 5 years survivors of Hodgkin´s disease. J Clin Oncol. 2007;25:1489-97.

8. Castellino SM, Geiger AM, Mertens AC. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.

9. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:1096-103.

10. Ng AK, Chi R, Li S. A prospective study of pulmonary function in Hodgkin´s lymphoma patients. Ann Oncol. 2008;19:1754-8.

11. Aleman BM, Van Leeuwen FE, Klokman WJ. Long-term cause specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-9.

12. Thompson CA, Mauch K, Havyer R. Care of the adult Hodgkin's lymphoma survivor. Am J Med. 2011;124:1106-12.

13. Aleman BM, van den Belt-Dusebout AW, Klokman WJ. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-86.

14. Meyer RM, Hoppe TR. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Hematology Am Soc Hematol Educ Program. 2012;2012:313-21.

15. Armitage JO. Early-Stage Hodgkin's Lymphoma. N Engl J Med. 2010;363:653- 62.

16. Swerdlow AJ, Higgins CD, Smith P. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol. 2011;29:4096-104.

17. Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patient. Ther Adv Hematol. 2011;2:111-9.

18. Dores GM, Metayer C, Curtis RE. Second malignant neoplasms among longterm survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–94.

19. Ng AK, Bernardo MP, Weller E. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-8.

20. Hodgson DC. Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323-9.

21. Crump M, Hodgson D. Secondary breast cancer in Hodgkin´s lymphoma survivors. J Clin Oncol. 2009;27:4229-31.

22. Veit-Rubin N, Rapiti E, Usel M. Risk, Characteristics, and Prognosis of Breast Cancer after Hodgkin's Lymphoma. The Oncologist. 2012;17:783-91.

23. Meyer R, Gospodarowicz M, Connors JM. Randomized comparison of ABVD chemotherapy with a strategy that incluyes radiation therapy in patients with limited stage Hodgkin´s Lymphoma: National Cancer Institute of Canada Clinical Trials Groupand the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634-42.

24. Herbs C, Rehan FA, Brillant C. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin´s lymphoma: a systematic rewiew. Haematologica. 2010;95:494-500.

25. Franklin J, Pluetschow A, Paus M. Second malignancy risk associated with treatment of Hodgkin´s lymphoma: meta-analysis of the randomized trials. Ann Oncol. 2006;17:1749-60.

26. Omer B, Kadan-Lottick NS, Roberts KB. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Brit J Haematol. 2012;158:615–25.

27. De Bruin ML, Sparidans J, van’t Veer MB. Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239-46.

28. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Brit J Haematol. 2011;154:23-3.

29. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin Lymphoma. Blood. 2011;117:1772-3.

30. Barbaro PM, Johnston K, Dalla-Poza L. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. 2011;22:2569-74.

31. Straus DJ, Portlock Carol S. Resultsof a prospective randomized clinical trial of doxorubicin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9.

32. Sieniawski M, Reineke T, Nogova L. Fertility in male patients with advanced Hodgkin lymphomatreated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71-6.

33. Ferme C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357:1916-27.

34. Dabaja B, Cox JD, Buchhols TA. Radiation therapy can still be used safely in combined modality approaches in patients with Hodgkin's lymphoma. J Clin Oncol. 2007;25:3-5.

35. Huang MD, Xiaoxue MD, Jennifer MR. Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice. Circ Am Heart Ass. 2010;121:615-6.